Summary
Global Markets Direct’s, ‘Obesity - Pipeline Review, H1 2016’, provides an overview of the Obesity pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Obesity
- The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects
- The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Obesity
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Obesity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Abeome Corporation
Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
Akron Molecules AG
Alize Pharma SAS
Amabiotics SAS
Ambrx, Inc.
Amgen Inc.
Arena Pharmaceuticals, Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
AtheroNova Inc.
Athersys, Inc.
Avaxia Biologics, Inc.
BioLingus AG
Biophytis SAS
BioRestorative Therapies, Inc.
BioTime, Inc.
Boehringer Ingelheim GmbH
Braasch Biotech LLC
Bristol-Myers Squibb Company
Camurus AB
Carmot Therapeutics, Inc.
Chronos Therapeutics Limited
CohBar, Inc.
CoMentis, Inc.
Corium International, Inc.
Daiichi Sankyo Company, Limited
Diabetica Limited
DiscoveryBiomed, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Esperion Therapeutics, Inc.
Eternygen GmbH
Euroscreen S.A.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Galenea Corp.
GlaxoSmithKline Plc
GTx, Inc.
HanAll Biopharma Co., Ltd.
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Helsinn Healthcare S.A.
Hyundai Pharmaceutical Co., Ltd.
Immungenetics AG
Intarcia Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Kissei Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
Lead Discovery Center GmbH
LEO Pharma A/S
LG Life Science LTD.
Magnus Life Science
MAKScientific, LLC
MedImmune, LLC
Merck & Co., Inc.
Mitochon Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Molecular Design International, Inc.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
nLife Therapeutics, S.L.
Nordic Bioscience A/S
Novo Nordisk A/S
ObeTherapy Biotechnology
Omeros Corporation
OPKO Health, Inc.
Orbis Biosciences, Inc.
Orexigen Therapeutics, Inc.
Pfizer Inc.
PharmaIN Corporation
Progenra, Inc.
Prometheon Pharma, LLC
Reviva Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc.
Saniona AB
Sanofi
Shanghai Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd.
Sinil Pharmaceutical Co., Ltd
Sirona Biochem Corp
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
Toray Industries, Inc.
Transition Therapeutics Inc.
Umecrine AB
Vicore Pharma AB
Viking Therapeutics, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xenetic Biosciences (UK) Limited
XL-protein GmbH
Zafgen Inc.
Zealand Pharma A/S
'
Table of Contents
Table of Contents 2
Introduction 7
Obesity Overview 8
Therapeutics Development 9
Obesity - Therapeutics under Development by Companies 11
Obesity - Therapeutics under Investigation by Universities/Institutes 20
Obesity - Pipeline Products Glance 23
Obesity - Products under Development by Companies 27
Obesity - Products under Investigation by Universities/Institutes 40
Obesity - Companies Involved in Therapeutics Development 43
Obesity - Therapeutics Assessment 141
Drug Profiles 160
Obesity - Recent Pipeline Updates 442
Obesity - Dormant Projects 481
Obesity - Discontinued Products 503
Obesity - Product Development Milestones 510
Appendix 517
List of Tables
Number of Products under Development for Obesity, H1 2016 35
Number of Products under Development for Obesity - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 38
Number of Products under Development by Companies, H1 2016 (Contd..1) 39
Number of Products under Development by Companies, H1 2016 (Contd..2) 40
Number of Products under Development by Companies, H1 2016 (Contd..3) 41
Number of Products under Development by Companies, H1 2016 (Contd..4) 42
Number of Products under Development by Companies, H1 2016 (Contd..5) 43
Number of Products under Development by Companies, H1 2016 (Contd..6) 44
Number of Products under Development by Companies, H1 2016 (Contd..7) 45
Number of Products under Investigation by Universities/Institutes, H1 2016 46
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 47
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 48
Comparative Analysis by Late Stage Development, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Development, H1 2016 51
Comparative Analysis by Unknown Stage Development, H1 2016 52
Products under Development by Companies, H1 2016 53
Products under Development by Companies, H1 2016 (Contd..1) 54
Products under Development by Companies, H1 2016 (Contd..2) 55
Products under Development by Companies, H1 2016 (Contd..3) 56
Products under Development by Companies, H1 2016 (Contd..4) 57
Products under Development by Companies, H1 2016 (Contd..5) 58
Products under Development by Companies, H1 2016 (Contd..6) 59
Products under Development by Companies, H1 2016 (Contd..7) 60
Products under Development by Companies, H1 2016 (Contd..8) 61
Products under Development by Companies, H1 2016 (Contd..9) 62
Products under Development by Companies, H1 2016 (Contd..10) 63
Products under Development by Companies, H1 2016 (Contd..11) 64
Products under Development by Companies, H1 2016 (Contd..12) 65
Products under Investigation by Universities/Institutes, H1 2016 66
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 67
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 68
Obesity - Pipeline by Abeome Corporation, H1 2016 69
Obesity - Pipeline by Advinus Therapeutics Ltd., H1 2016 70
Obesity - Pipeline by Aegis Therapeutics, LLC, H1 2016 71
Obesity - Pipeline by Akron Molecules AG, H1 2016 72
Obesity - Pipeline by Alize Pharma SAS, H1 2016 73
Obesity - Pipeline by Amabiotics SAS, H1 2016 74
Obesity - Pipeline by Ambrx, Inc., H1 2016 75
Obesity - Pipeline by Amgen Inc., H1 2016 76
Obesity - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 77
Obesity - Pipeline by AstraZeneca Plc, H1 2016 78
Obesity - Pipeline by Asubio Pharma Co., Ltd., H1 2016 79
Obesity - Pipeline by AtheroNova Inc., H1 2016 80
Obesity - Pipeline by Athersys, Inc., H1 2016 81
Obesity - Pipeline by Avaxia Biologics, Inc., H1 2016 82
Obesity - Pipeline by BioLingus AG, H1 2016 83
Obesity - Pipeline by Biophytis SAS, H1 2016 84
Obesity - Pipeline by BioRestorative Therapies, Inc., H1 2016 85
Obesity - Pipeline by BioTime, Inc., H1 2016 86
Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2016 87
Obesity - Pipeline by Braasch Biotech LLC, H1 2016 88
Obesity - Pipeline by Bristol-Myers Squibb Company, H1 2016 89
Obesity - Pipeline by Camurus AB, H1 2016 90
Obesity - Pipeline by Carmot Therapeutics, Inc., H1 2016 91
Obesity - Pipeline by Chronos Therapeutics Limited, H1 2016 92
Obesity - Pipeline by CohBar, Inc., H1 2016 93
Obesity - Pipeline by CoMentis, Inc., H1 2016 94
Obesity - Pipeline by Corium International, Inc., H1 2016 95
Obesity - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 96
Obesity - Pipeline by Diabetica Limited, H1 2016 97
Obesity - Pipeline by DiscoveryBiomed, Inc., H1 2016 98
Obesity - Pipeline by Eisai Co., Ltd., H1 2016 99
Obesity - Pipeline by Eli Lilly and Company, H1 2016 100
Obesity - Pipeline by Esperion Therapeutics, Inc., H1 2016 101
Obesity - Pipeline by Eternygen GmbH, H1 2016 102
Obesity - Pipeline by Euroscreen S.A., H1 2016 103
Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 104
Obesity - Pipeline by FibroGen, Inc., H1 2016 105
Obesity - Pipeline by Galenea Corp., H1 2016 106
Obesity - Pipeline by GlaxoSmithKline Plc, H1 2016 107
Obesity - Pipeline by GTx, Inc., H1 2016 108
Obesity - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 109
Obesity - Pipeline by Handok Inc., H1 2016 110
Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 111
Obesity - Pipeline by Helsinn Healthcare S.A., H1 2016 112
Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 113
Obesity - Pipeline by Immungenetics AG, H1 2016 114
Obesity - Pipeline by Intarcia Therapeutics, Inc., H1 2016 115
Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 116
Obesity - Pipeline by Jenrin Discovery, Inc., H1 2016 117
Obesity - Pipeline by Johnson & Johnson, H1 2016 118
Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 119
Obesity - Pipeline by Kowa Company, Ltd., H1 2016 120
Obesity - Pipeline by Lead Discovery Center GmbH, H1 2016 121
Obesity - Pipeline by LEO Pharma A/S, H1 2016 122
Obesity - Pipeline by LG Life Science LTD., H1 2016 123
Obesity - Pipeline by Magnus Life Science, H1 2016 124
Obesity - Pipeline by MAKScientific, LLC, H1 2016 125
Obesity - Pipeline by MedImmune, LLC, H1 2016 126
Obesity - Pipeline by Merck & Co., Inc., H1 2016 127
Obesity - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016 128
Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 129
Obesity - Pipeline by Molecular Design International, Inc., H1 2016 130
Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016 131
Obesity - Pipeline by Nimbus Therapeutics, LLC, H1 2016 132
Obesity - Pipeline by nLife Therapeutics, S.L., H1 2016 133
Obesity - Pipeline by Nordic Bioscience A/S, H1 2016 134
Obesity - Pipeline by Novo Nordisk A/S, H1 2016 135
Obesity - Pipeline by ObeTherapy Biotechnology, H1 2016 136
Obesity - Pipeline by Omeros Corporation, H1 2016 137
Obesity - Pipeline by OPKO Health, Inc., H1 2016 138
Obesity - Pipeline by Orbis Biosciences, Inc., H1 2016 139
Obesity - Pipeline by Orexigen Therapeutics, Inc., H1 2016 140
Obesity - Pipeline by Pfizer Inc., H1 2016 141
Obesity - Pipeline by PharmaIN Corporation, H1 2016 142
Obesity - Pipeline by Progenra, Inc., H1 2016 143
Obesity - Pipeline by Prometheon Pharma, LLC, H1 2016 144
Obesity - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 145
Obesity - Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016 146
Obesity - Pipeline by Saniona AB, H1 2016 147
Obesity - Pipeline by Sanofi, H1 2016 148
Obesity - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 149
Obesity - Pipeline by Shionogi & Co., Ltd., H1 2016 150
Obesity - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 151
Obesity - Pipeline by Sirona Biochem Corp, H1 2016 152
Obesity - Pipeline by Sorrento Therapeutics, Inc., H1 2016 153
Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 154
Obesity - Pipeline by Suven Life Sciences Ltd., H1 2016 155
Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 156
Obesity - Pipeline by Toray Industries, Inc., H1 2016 157
Obesity - Pipeline by Transition Therapeutics Inc., H1 2016 158
Obesity - Pipeline by Umecrine AB, H1 2016 159
Obesity - Pipeline by Vicore Pharma AB, H1 2016 160
Obesity - Pipeline by Viking Therapeutics, Inc., H1 2016 161
Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016 162
Obesity - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 163
Obesity - Pipeline by XL-protein GmbH, H1 2016 164
Obesity - Pipeline by Zafgen Inc., H1 2016 165
Obesity - Pipeline by Zealand Pharma A/S, H1 2016 166
Assessment by Monotherapy Products, H1 2016 167
Assessment by Combination Products, H1 2016 168
Number of Products by Stage and Target, H1 2016 170
Number of Products by Stage and Mechanism of Action, H1 2016 177
Number of Products by Stage and Route of Administration, H1 2016 183
Number of Products by Stage and Molecule Type, H1 2016 185
Obesity Therapeutics - Recent Pipeline Updates, H1 2016 468
Obesity - Dormant Projects, H1 2016 507
Obesity - Dormant Projects (Contd..1), H1 2016 508
Obesity - Dormant Projects (Contd..2), H1 2016 509
Obesity - Dormant Projects (Contd..3), H1 2016 510
Obesity - Dormant Projects (Contd..4), H1 2016 511
Obesity - Dormant Projects (Contd..5), H1 2016 512
Obesity - Dormant Projects (Contd..6), H1 2016 513
Obesity - Dormant Projects (Contd..7), H1 2016 514
Obesity - Dormant Projects (Contd..8), H1 2016 515
Obesity - Dormant Projects (Contd..9), H1 2016 516
Obesity - Dormant Projects (Contd..10), H1 2016 517
Obesity - Dormant Projects (Contd..11), H1 2016 518
Obesity - Dormant Projects (Contd..12), H1 2016 519
Obesity - Dormant Projects (Contd..13), H1 2016 520
Obesity - Dormant Projects (Contd..14), H1 2016 521
Obesity - Dormant Projects (Contd..15), H1 2016 522
Obesity - Dormant Projects (Contd..16), H1 2016 523
Obesity - Dormant Projects (Contd..17), H1 2016 524
Obesity - Dormant Projects (Contd..18), H1 2016 525
Obesity - Dormant Projects (Contd..19), H1 2016 526
Obesity - Dormant Projects (Contd..20), H1 2016 527
Obesity - Dormant Projects (Contd..21), H1 2016 528
Obesity - Discontinued Products, H1 2016 529
Obesity - Discontinued Products (Contd..1), H1 2016 530
Obesity - Discontinued Products (Contd..2), H1 2016 531
Obesity - Discontinued Products (Contd..3), H1 2016 532
Obesity - Discontinued Products (Contd..4), H1 2016 533
Obesity - Discontinued Products (Contd..5), H1 2016 534
Obesity - Discontinued Products (Contd..6), H1 2016 535
List of Figures
Number of Products under Development for Obesity, H1 2016 35
Number of Products under Development for Obesity - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 37
Number of Products under Investigation by Universities/Institutes, H1 2016 46
Comparative Analysis by Late Stage Development, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Products, H1 2016 51
Assessment by Monotherapy Products, H1 2016 167
Assessment by Combination Products, H1 2016 168
Number of Products by Top 10 Targets, H1 2016 169
Number of Products by Stage and Top 10 Targets, H1 2016 169
Number of Products by Top 10 Mechanism of Actions, H1 2016 176
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 176
Number of Products by Routes of Administration, H1 2016 182
Number of Products by Stage and Routes of Administration, H1 2016 182
Number of Products by Top 10 Molecule Types, H1 2016 184
Number of Products by Stage and Top 10 Molecule Types, H1 2016 184
